SilcsBio and Dalriada Drug Discovery Launch Partnership to Create a Rapid Drug Discovery Service SuiteJune 11, 2020SilcsBio and Dalriada to tap areas of expertise in drug design and development to accelerate clients’ programs in development of therapeutic treatments against diseases with unmet needs, initiated with COVID-19 FOR IMMEDIATE RELEASE: June 11, 2020,...
GEn1E Lifesciences, a Y Combinator-Backed Company, Granted Exclusive License for University of Maryland, Baltimore Drug Portfolio CompoundDecember 3, 2019PALO ALTO, Calif. and BALTIMORE, Dec. 3, 2019 /PRNewswire/ — GEn1E Lifesciences Inc., a Y Combinator-backed biotech startup focused on curing inflammatory and age-related diseases, announced today that it has acquired an exclusive, worldwide and...
New SILCS-MC Study Demonstrates Improved Performance with Machine Learning OptimizationMay 16, 2019May 16, 2019, Baltimore, MD – SilcsBio, a company that develops commercial software and related services for structure-based drug design, today announced that established Site-identification by ligand competitive saturation-Monte Carlo (SILCS-MC)...
SilcsBio, LLC Announces Release of CGenFF 2.3.0April 26, 2019Baltimore, MD, 26 April, 2019 – In ongoing efforts to improve the coverage of the CGenFF program, version 2.3.0 of the CGenFF program improves support for a variety of molecules via explicit parametrization of the molecules outlined below and...
Sygnature Discovery announces collaboration with software firm SilcsBioApril 17, 2019Nottingham, UK – 17th April 2019 – Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has today announced a collaboration with SilcsBio, a scientific software company focused on high-throughput...
SilcsBio, LLC Receives NIH Funding to Expand Offerings in BiologicsApril 11, 2019FOR IMMEDIATE RELEASE: April 11, 2019 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives NIH Funding to Expand Offerings in Biologics Baltimore, Maryland: SilcsBio, LLC announced today a $225,000 award...
SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design SoftwareJuly 12, 2018FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio)...
SILCS-MC ranks top 10 on Free Energy Set 1 in the D3R Grand Challenge 2 on FXRMarch 26, 2018Grand Challenge 2 from D3R provided a farnesoid X receptor (FXR) target dataset to participants, which was used to test the performance of various computational approaches. SilcsBio’s SILCS-MC approach ranked 4th in Stage 1 and 6th in Stage 2 on...
SilcsBio, LLC Announces Release of CGenFF 2.1.0April 4, 2017Baltimore, MD, 4 March 2017 – In ongoing efforts to improve the coverage of the CGenFF program, version 2.1.0 of the CGenFF program extends support to the S-P bond found in the GTP-gamma like molecules. Bonded parameters and charge-distribution...